

General information about company	
Name of The Company	MARKSANS PHARMA LIMITED
BSE Scrip Code	524404
NSE Symbol	MARKSANS
MSE Symbol	NA
Date of Start of Financial Year	01-04-2024
Date of End of Financial Year	31-03-2025
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2024
Date of End of Reporting Period	30-09-2024
Level of rounding to be used in disclosing related party transactions	Millions
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	13-11-2023
Indicate Company website link for updated RPT policy of the Company	https://marksanspharma.com/pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdf

Related party transactions

Related party transactions													Additional disclosure of related parties to loans, inter-company transactions, etc. These details		
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness incurred to make or give loans, corporate deposits, advances investments		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost
1	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Sale of goods or services		2177.41	Nil	153.66	0	0			
2	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	355.69	0	0			
3	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	1026.57	0	0			
4	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	3246.75	0	0			
5	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	REIMBURSEMENT OF EXPENSES		Nil	6.18	0	0			
6	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Any other transaction	Trade Receivable		Nil	0	495.86	330.49			
7	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	-34.71	103.67			
8	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	-861.98	-888.62			
9	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	2629.15	3806.41			
10	Marksans Pharma	AAACT3153G	Marksans Pharma UK	ZZZZZ9999Z	Wholly owned	Dividend received			Nil	263.69	0	0			

	Limited		Limited		subsidiary											
11	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable		Nil	0	0.43	0.46				
12	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable		Nil	0	0.84	0.89				
13	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable		Nil	0	0.48	0.48				
14	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Promoter & Key Managerial Personnel	Remuneration			Nil	39.16	0	0				
15	Marksans Pharma Limited	AAACT3153G	Sandra Saldanha	ALRPS8186P	Promoter & Key Managerial Personnel	Remuneration			Nil	3.53	0	0				
16	Marksans Pharma Limited	AAACT3153G	Jitendra Sharma	AJCPS5121K	Key Managerial Personnel	Remuneration			Nil	9.68	0	0				
17	Marksans Pharma Limited	AAACT3153G	Harshavardhan Panigrahi	AKTPP1644A	Key Managerial Personnel	Remuneration			Nil	1.43	0	0				
18	Marksans Pharma Limited	AAACT3153G	Vardhman Jain	ACWPJ0702A	Key Managerial Personnel	Remuneration			Nil	13.42	0	0				
19	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Promoter & Key Managerial Personnel	Any other transaction	Rent Paid		Nil	5.33	0	0				
Total value of transaction during the reporting period										5125.09						

Text Block	
Textual Information(1)	
Textual Information(2)	
Textual Information(3)	
Textual Information(4)	
Textual Information(5)	
Textual Information(6)	
Textual Information(7)	
Textual Information(8)	
Textual Information(9)	
Textual Information(10)	
Textual Information(11)	
Textual Information(12)	
Textual Information(13)	
Textual Information(14)	Remuneration of Rs. 33.14 million is drawn from the Company and the remaining amount (Rs. 6.02 million) is the remunration drawn from subsidiary Company.
Textual Information(15)	
Textual Information(16)	
Textual Information(17)	
Textual Information(18)	
Textual Information(19)	

